Evidence
Neuroreport. 2023 Aug 24;34(11):546-550. doi: 10.1097/WNR.0000000000001923. Epub 2023 Jun 7.
ABSTRACT
Tau protein accumulation in the brain is thought to be one of the causes of Alzheimer’s disease (AD). Recent studies found that the choroid plexus (CP) has a role in β-amyloid and tau protein clearance in the brain. We evaluated the relationships between CP volume and the ß-amyloid and tau protein depositions. Participants were 20 patients with AD and 35 healthy subjects who underwent MRI and PET scanning using the ß-amyloid tracer 11C-PiB and the tau/inflammatory tracer 18F-THK5351. We computed the volume of the CP and estimated the relationships between the CP volume and ß-amyloid and tau protein/inflammatory deposition by Spearman’s correlation test. The CP volume was significantly positively correlated with both the standardized uptake value ratio (SUVR) of 11C-PiB and the SUVR of 18F-THK5351 in all participants. The CP volume was also significantly positively correlated with the SUVR of 18F-THK5351in patients with AD. Our data suggested that the volume of the CP was a good biomarker for the evaluation of tau deposition and neuroinflammation.
PMID:37384934 | DOI:10.1097/WNR.0000000000001923
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Relationship between the tau protein and choroid plexus volume in Alzheimer’s disease
🌐 90 Days
VR Related Evidence Matrix
- In vivo PET classification of tau pathologies in patients with frontotemporal dementia
- G-protein coupled estrogen receptor 1, amyloid-β, and tau tangles in older adults
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- Traumatic Brain Injury in Mice Generates Early-Stage Alzheimer's Disease Related Protein Pathology that Correlates with Neurobehavioral Deficits
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly
- Biomarkers of Neurodegeneration and Alzheimer's Disease Neuropathology in Adolescents and Young Adults with Youth-Onset Type 1 or Type 2 Diabetes: A Proof-of-Concept Study
- Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
- The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Association of CSF biomarkers with MRI brain changes in Alzheimer's disease
- Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients
- A multiscale closed-loop neurotoxicity model of Alzheimer's disease progression explains functional connectivity alterations
- PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Tau accumulation and its spatial progression across the Alzheimer's disease spectrum
- Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment
- Deep learning segmentation of the choroid plexus from structural magnetic resonance imaging (MRI): validation and normative ranges across the adult lifespan
- D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease
- Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort
- Predicting functional decline in aging and Alzheimer's disease with PET-based Braak staging
- β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer's disease
- Bacteroidota inhibit microglia clearance of amyloid-beta and promote plaque deposition in Alzheimer's disease mouse models
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models
- Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)
- Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry
- Reactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection
- Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
- Personalized whole-brain neural mass models reveal combined Ab and tau hyperexcitable influences in Alzheimer's disease
- Is Alzheimer disease a disease?
- Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
- Disease and brain region specific immune response profiles in neurodegenerative diseases with pure and mixed protein pathologies
- Specific Association of Worry With Amyloid-β But Not Tau in Cognitively Unimpaired Older Adults
- Plasma Leptin and Alzheimer Protein Pathologies Among Older Adults
- Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer's disease
- Multiple system atrophy with amyloid-b-predominant Alzheimer's disease neuropathologic change
- Kinetic modeling of the monoamine oxidase-B radioligand [(18)F]SMBT-1 in human brain with positron emission tomography
- Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer's disease seed-dependent formation of tau aggregates
- Inferior Frontal Sulcal Hyperintensities on Brain MRI Are Associated with Amyloid Positivity beyond Age-Results from the Multicentre Observational DELCODE Study
- Peripheral hearing loss at age 70 predicts brain atrophy and associated cognitive change
- Impact of amyloid and tau positivity on longitudinal brain atrophy in cognitively normal individuals
- Effect of Natural Osmolytes on Recombinant Tau Monomer: Propensity of Oligomerization and Aggregation
- Differential Regulation of Neurotrophic Factors During Pathogenic Tau-Aggregation in a Tau Transgenic Mouse Model for Alzheimer's Disease: A Protocol for Double-Labeling mRNA by In Situ Hybridization and Protein Epitopes by Immunohistochemistry
- Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial
- Influences of amyloid-beta and tau on white matter neurite alterations in dementia with Lewy bodies
- The Relationship of Cerebrospinal Fluid Biomarkers and Cognitive Performance in Frontotemporal Dementia
- Passive immunotherapy for Alzheimer's disease: challenges & future directions
- Impaired Glymphatic Flow on Diffusion Tensor MRI as a Marker of Neurodegeneration in Alzheimer's Disease: Correlation with Gray Matter Volume Loss and Cognitive Decline Independent of Cerebral Amyloid Deposition
- Impaired Glymphatic Flow on Diffusion Tensor MRI as a Marker of Neurodegeneration in Alzheimer's Disease: Correlation with Gray Matter Volume Loss and Cognitive Decline Independent of Cerebral Amyloid Deposition
- Quantitative Brain Amyloid PET
- Data-driven decomposition and staging of flortaucipir uptake in Alzheimer's disease
- Traumatic Brain Injury and Post-Traumatic Stress Disorder and Their Influence on Development and Pattern of Alzheimer's Disease Pathology in Later Life
- Fixel-based analysis reveals tau-related white matter changes in early stages of Alzheimer's disease
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Involvement of the glymphatic/meningeal lymphatic system in Alzheimer's disease: insights into proteostasis and future directions
- Types of memory, dementia, Alzheimer's disease, and their various pathological cascades as targets for potential pharmacological drugs
- Total Tau Protein Mediates the Association of Ischemic Cerebrovascular Disease with Cognitive Decline
- Pathogenic soluble tau peptide disrupts endothelial calcium signaling and vasodilation in the brain microvasculature
- Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model
- Long-Term High-Fat Diet Consumption Aggravates β-Amyloid Deposition and Tau Pathology Accompanied by Microglial Activation in an Alzheimer's Disease Model
- APOE ε4 carrier status modifies plasma p-tau181 concentrations in cognitively healthy super-seniors
- Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments
Evidence Blueprint
Relationship between the tau protein and choroid plexus volume in Alzheimer’s disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Relationship between the tau protein and choroid plexus volume in Alzheimer’s disease
🌐 365 Days
VR Related Evidence Matrix
- Blood-brain barrier breakdown is linked to tau pathology and neuronal injury in a differential manner according to amyloid deposition
- Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest
- A data-driven study of Alzheimer's disease related amyloid and tau pathology progression
- Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation
- Preclinical Characterization of the Tau PET Tracer [18F]SNFT-1: Comparison of Tau PET Tracers
- In vivo PET classification of tau pathologies in patients with frontotemporal dementia
- Tau protein spreads through functionally connected neurons in Alzheimer's disease: a combined MEG/PET study
- Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework
- G-protein coupled estrogen receptor 1, amyloid-β, and tau tangles in older adults
- APOEε4 potentiates amyloid β effects on longitudinal tau pathology
- Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)
- Age-, sex-, and pathology-related variability in brain structure and cognition
- Investigating neural dysfunction with abnormal protein deposition in Alzheimer's disease through magnetic resonance spectroscopic imaging, plasma biomarkers, and positron emission tomography
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- Association of Neurofilament Light Chain, [18F]PI-2620 Tau-PET, TSPO-PET, and Clinical Progression in Patients With β-Amyloid-Negative CBS
- Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity
- Performance of a [18F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies
- Mistranslation-associated perturbations of proteostasis do not promote accumulation of amyloid beta and plaque deposition in aged mouse brain
- Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology
- Alpha-, Beta-, and Gamma-Secretase, Amyloid Precursor Protein, and Tau Protein Genes in the Hippocampal CA3 Subfield in an Ischemic Model of Alzheimer's Disease with Survival up to 2 Years
- Tau and Alzheimer's disease: Past, present and future
- Localized proteomic differences in the choroid plexus of Alzheimer's disease and epilepsy patients
- Polypathologic associations with grey matter atrophy in neurodegenerative disease
- Detection of β-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of alzheimer's disease
- Traumatic Brain Injury in Mice Generates Early-Stage Alzheimer's Disease Related Protein Pathology that Correlates with Neurobehavioral Deficits
- Suspecting Non-Alzheimer's Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images
- Effects of the APOEɛ4 Allele on the Relationship Between Tau and Amyloid-β in Early- and Late-Onset Alzheimer's Disease
- Passive tau-based immunotherapy for tauopathies
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly
- Biomarkers of Neurodegeneration and Alzheimer's Disease Neuropathology in Adolescents and Young Adults with Youth-Onset Type 1 or Type 2 Diabetes: A Proof-of-Concept Study
- CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegeneration
- Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
- Head-to-head comparison of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases
- Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals
- The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome
- Ketone bodies mediate alterations in brain energy metabolism and biomarkers of Alzheimer's disease
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- White matter hyperintensity volume modifies the association between CSF vascular inflammatory biomarkers and regional FDG-PET along the Alzheimer's disease continuum
- p-tau Ser356 is associated with Alzheimer's disease pathology and is lowered in brain slice cultures using the NUAK inhibitor WZ4003
- A microtubule stabilizer ameliorates protein pathogenesis and neurodegeneration in mouse models of repetitive traumatic brain injury
- Local structural preferences in shaping tau amyloid polymorphism
- Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Development of small-molecule Tau-SH3 interaction inhibitors that prevent amyloid-β toxicity and network hyperexcitability
- Retina pathology as a target for biomarkers for Alzheimer's disease: Current status, ophthalmopathological background, challenges, and future directions
- Association of CSF biomarkers with MRI brain changes in Alzheimer's disease
- Primary Hypothyroidism and Alzheimer's Disease: A Tale of Two
- Tau here, tau there, tau almost everywhere: Clarifying the distribution of tau in the adult CNS
- Associations between sex, body mass index and the individual microglial response in Alzheimer's disease
- Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients
- Structure-Based Discovery of A Small Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) that Significantly Reduces Alzheimer's Disease Neuropathology
- Florbetapir PET-assessed demyelination is associated with faster tau accumulation in an APOE ε4-dependent manner
- High burdens of phosphorylated tau protein and distinct precuneus atrophy in sporadic early-onset Alzheimer's disease
- CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease
- Biochemical approaches to assess the impact of post-translational modifications on pathogenic tau conformations using recombinant protein
- Effects of heterologous human tau protein expression in yeast models of proteotoxic stress response
- A multiscale closed-loop neurotoxicity model of Alzheimer's disease progression explains functional connectivity alterations
- Utility of amyloid PET Imaging in a Memory Clinic
- Evaluation of possible neuroprotective effects of virgin coconut oil on aluminum-induced neurotoxicity in an in vitro Alzheimer's disease model
- PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease
- Mechanisms behind changes of neurodegeneration biomarkers in plasma induced by sleep deprivation
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease